BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Block & Leviton LLP Investigates Abiomed (ABMD) and Certain of Its Officers and Directors for Possible Violations of the Federal Securities Laws


11/5/2012 1:01:53 PM

BOSTON, Nov. 2, 2012 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, is investigating possible securities law violations involving Abiomed Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD) following the Company's disclosure of a Department of Justice investigation into "marketing and labeling issues" of its Impella 2.5 system.

On November 1, 2012, the Company announced that, on October 26, 2012, it was informed that the United States Attorney's Office for the District of Columbia was conducting an investigation into Abiomed's marketing and labeling of its Impella 2.5 system. This investigation follows reports that, in June 2011, Abiomed received a warning letter from the U.S. Food and Drug Administration about improper marketing of the Impella 2.5 system for unapproved uses.

News of the DOJ investigation shocked the market and the Company's stock price fell by more than 32% - dropping from $19.82 per share on October 31, 2012 to close at $13.61 per share on November 1, 2012.

Block & Leviton's investigation seeks to determine, among other things, whether Abiomed or its officers and directors have violated the federal securities laws. If you have any information relevant to this investigation, or have questions about your legal rights, please contact attorney Steven P. Harte of Block & Leviton LLP at (617) 398-5600 or email him at Steven@blockesq.com.

Block & Leviton is a Boston-based law firm representing investors for violations of securities laws. The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.

This notice may constitute attorney advertising.

Contact:

BLOCK & LEVITON LLP


Steven P. Harte, Esq.


(617) 398-5600


Steven@blockesq.com

SOURCE Block & Leviton LLP



Read at BioSpace.com

Abiomed
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->